Challenges of using single domain antibodies as new modalities of multifunctional biologics
01 Dec 2025
Formats & Scaffolds
-
How can multispecific antibody fragments and scaffolds rival the well-established bispecific Antibody formats in terms of developability and PK?
- Given the size of the bispecifics development pipeline and the decline in VC funding, how should small biotech companies go ahead?
- How should the immunogenicity risk be mitigated?
- What are the sweet spot applications for multispecifics?
